Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Collaboration › Details

Inpart–Norstella: business services, 202409– collab integrating Evaluate data into Deal CRM of Inpart


Period Period 2024-02-29
Organisation Partner, 1st Inpart SAS
  Today Inpart (Group)
  Group Inpart (Group)
Product Product  Deal biopharma partnering CRM
Persons Person Toulemonde, Gilles (Inova Software 201809 CEO + Co-Founder)
  Person 2 Kelley, Chris (Norstella 202402 Chief Revenue Officer at Evaluate)

Inpart SAS. (2/29/24). "Press Release: Inpart and Evaluate Announce Strategic Partnership to Optimize Biopharma Dealmaking". Lyon.

In a landmark collaboration, Inpart (previously Inova), a trailblazing software provider specializing in biopharma partnering, and Evaluate, a leading insights provider for the biopharma industry and part of Norstella, have officially announced their strategic partnership. This alliance will empower biopharma partnering teams to assess their opportunities quickly and efficiently with decisive data, in the same place.

Inpart's flagship product, Deal, enables pharmaceutical companies and biotechs to identify, evaluate, and collaborate seamlessly on strategic partnerships. Paired with Evaluate’s unparalleled AI-enabled intelligence and forecasting solutions, this partnership promises to enhance the impact of critical data by providing direct accessibility for dealmakers when identifying and evaluating opportunities.

"Incorporating Evaluate into our partnering CRM is integrating data into organization. This is increasing productivity by increasing data quality and integrity. All connected sources are automatically synced and updated to save time and support informed decision-making. Essentially, we're empowering our clients to establish trust in their data for the purpose of achieving operational excellence."

Gilles Toulemonde
CEO at Inpart

"This collaboration is strategically designed to foster robust dissemination and collaboration within dealmaking teams by directly embedding Evaluate data in their Inpart workflow – enabling more informed decision-making to help smooth the path of lifesaving therapies from pipeline to patient."

Chris Kelley
Chief Revenue Officer at Evaluate

This strategic partnership underscores the commitment of both companies to advancing the biopharma industry by facilitating stronger collaboration and empowering decision-makers with the tools they need to drive success.

About Inpart

Inpart is the trusted partner for biopharma and science partnering. The platformprovide comprehensive solutions to facilitate, optimize and track interactions in the biopharma, scientific and academic sectors. Inpart’s technology is the preferred choice for more than 6,500 companies including 45/50 of the world's leading pharma companies, 25/25 global R&D intensive firms, 25/25 top EU R&D intensive firms and over 200 of the world’s leading universities. Connect, a cutting-edge match making platform, serves as the backbone of a thriving network, uniting over 6,500 industry professionals, academic organizations, biotech companies and investors. Through Connect, Inpart empower users to enhance their visibility, expedite partner discovery, and gain invaluable strategic insights.

Inpart's partnering CRM, Deal, is tailored specifically to meet the unique demands of the biopharma sector. Deal streamlines the collaboration and alliance management phases of biopharma partnerships, ensuring efficient and organized operations in executing Biopharma deals.

Discover the suite of products and services: and follow us on LinkedIn.

Contact information:
Sarah Issa, CMO
+33 6 24 86 81 69

About Evaluate

Since 1996, Evaluate, a Norstella company, has provided the life sciences industry with the data, insight and intelligence to facilitate confident decision making on high-value investments in treatments and markets. We enable our clients to embed our proprietary and industry data into their workflows, tools and processes so they can work more effectively and efficiently.

For more information about Evaluate, visit and follow us on LinkedIn and Twitter.

About Norstella

Norstella consists of several prominent pharmaceutical solutions providers—Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group—united by a shared mission: to smooth the path to life-saving therapies for patients and providers. Norstella offers comprehensive insights throughout the drug development lifecycle, leveraging unparalleled data, cutting-edge technology, and expert insights and consultancy. For more information, visit Norstella and follow on LinkedIn.

Contact information:

Carolyn Hall, Director of Content & Thought Leadership Marketing
+44 20 7539 1814

Record changed: 2024-03-19


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Inpart (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group World of Partnering Opportunities 650x300px

» top